What is the preferred course of action after a diagnosis of Kaposi Sarcoma?

What is the preferred course of action after a diagnosis of Kaposi Sarcoma?

• A. Immediate surgery
• B. Start HAART therapy
• C. Regular monitoring only
• D. Topical antifungal application

Answer: (B)

The preferred course of action after a diagnosis of Kaposi Sarcoma is to start HAART therapy. This is because Kaposi Sarcoma is often associated with immunocompromise, particularly in patients with HIV/AIDS. Highly active antiretroviral therapy (HAART) is crucial in managing the underlying HIV infection, which not only helps to restore immune function but can also lead to the regression of Kaposi Sarcoma lesions. By effectively controlling the viral load and improving the immune response, patients may experience a decrease in the severity and extent of their cancer. In contrast, the other options are less appropriate. Immediate surgery is typically not the first-line treatment for Kaposi Sarcoma since the disease can be widespread and multifocal. Regular monitoring may not be sufficient given the tumor's potential to progress, especially in someone with compromised immunity. Lastly, topical antifungal applications would not address the underlying cancer or the associated viral infection, rendering this option ineffective. Starting HAART therapy is essential not only for managing Kaposi Sarcoma but also for improving the overall health and well-being of the patient.

The preferred course of action after a diagnosis of Kaposi Sarcoma is to start HAART therapy. This is because Kaposi Sarcoma is often associated with immunocompromise, particularly in patients with HIV/AIDS. Highly active antiretroviral therapy (HAART) is crucial in managing the underlying HIV infection, which not only helps to restore immune function but can also lead to the regression of Kaposi Sarcoma lesions. By effectively controlling the viral load and improving the immune response, patients may experience a decrease in the severity and extent of their cancer.

In contrast, the other options are less appropriate. Immediate surgery is typically not the first-line treatment for Kaposi Sarcoma since the disease can be widespread and multifocal. Regular monitoring may not be sufficient given the tumor's potential to progress, especially in someone with compromised immunity. Lastly, topical antifungal applications would not address the underlying cancer or the associated viral infection, rendering this option ineffective. Starting HAART therapy is essential not only for managing Kaposi Sarcoma but also for improving the overall health and well-being of the patient.